Table 2.
Differentially expressed genes in wild-type and PPTA−/− mice 8 h after CLP-induced sepsis, compared with sham-operated mice.
| Fold increase/decreasea |
||
|---|---|---|
| Gene | Wild-type CLP | PPTA−/− CLP |
| Inflammatory response | ||
| Serum amyloid A 3b | 4.21 | 54.52 |
| Chemokine (C-C motif) ligand 2b | 5.52 | 54.37 |
| Fc receptor, IgE, high affinity I, γ polypeptide | 2.30 | 7.15 |
| Chemokine (C-X-C motif) ligand 10b | 5.04 | 12.58 |
| Chemokine (C-C motif) receptor 1 | 4.66 | 15.52 |
| Chemokine (C-X-C motif) ligand 1 | 5.35 | 37.74 |
| Interleukin-1 receptor antagonistb | 6.23 | 125.25 |
| Chemokine (C-X-C motif) ligand 2b | 107.41 | 114.76 |
| CD14 antigen | 7.93 | 13.70 |
| Toll-like receptor 13 | 3.72 | 5.52 |
| Chemokine (C-C motif) ligand 4b | 3.55 | 17.59 |
| Interleukin-1βb | 6.77 | 8.85 |
| Selectin, platelet | 2.57 | 12.03 |
| Toll-like receptor 2 | 4.09 | 6.09 |
| Complement component 5a receptor 1 | 3.19 | 6.50 |
| Tumor necrosis factor receptor superfamily, member 1b | 2.15 | 8.14 |
| CD28 antigen | 1.87 | 2.56 |
| Chemokine (C-C motif) ligand 3b | 13.05 | 73.16 |
| Toll-like receptor 6 | 2.18 | 2.68 |
| Tumor necrosis factor receptor superfamily, member 1a | –c | 2.09 |
| Mitogen-activated protein kinase kinase 3 | – | 2.12 |
| Oxidized low-density lipoprotein (lectin-like) receptor 1 | – | 5.51 |
| Orosomucoid 1 | – | 34.00 |
| Signal transducer and activator of transcription 3 | – | 2.63 |
| Chemokine (C-C motif) receptor 2b | – | 5.26 |
| Chemokine (C-C motif) ligand 22 | – | 2.83 |
| Fc receptor, IgG, low affinity IIb | – | 9.90 |
| Fc receptor, IgG, low affinity III | – | 6.59 |
| Toll-like receptor 5 | – | −2.24d |
| Toll-like receptor 1 | – | 3.53 |
| CD44 antigen | – | 3.62 |
| Signal transducer and activator of transcription 5a | – | 2.44 |
| Phospholipase a2, group VII (platelet-activating factor acetylhydrolase, plasma) | – | 7.59 |
| Chemotaxis | ||
| Chemokine (C-C motif) ligand 9 | 2.27 | 10.09 |
| s100 calcium binding protein A8 (calgranulin A) | 2.68 | – |
| Formyl peptide receptor 1 | 9.01 | 48.18 |
| Chemokine (C-C motif) ligand 17 | – | 8.49 |
| Chemokine (C-C motif) receptor 5b | – | 14.45 |
| Cysteine-rich protein 61 | – | −5.25 |
| Integrin β 2 | – | 3.68 |
| Interleukin-16 | – | 3.71 |
| Chemokine (C-C motif) ligand 6 | – | 3.63 |
| Leukocyte activation | ||
| CD80 antigen | 3.19 | 2.60 |
| CD52 antigen | 1.92 | 2.27 |
| Interleukin-12a | – | 2.61 |
| Growth arrest and DNA-damage-inducible 45 γ | – | 4.21 |
| fas (TNF receptor superfamily member) | – | 4.82 |
| CD40 antigen | – | 2.10 |
| Response to wounding | ||
| Coagulation factor XIII, a1 subunit | 2.12 | 4.17 |
| Gap junction membrane channel protein α 1 | – | 3.25 |
| Coagulation factor X | – | 17.55 |
| Coagulation factor VII | – | 2.43 |
| Fibrinogen, γ polypeptide | – | 11.57 |
| Response to bacterium | ||
| Cathelicidin antimicrobial peptide | 5.33 | 40.93 |
| Peptidoglycan recognition protein 1 | 4.44 | 2.26 |
| Lipopolysaccharide-binding protein | – | 2.46 |
| Regulation of cellular process | ||
| Protein tyrosine phosphatase, nonreceptor type 11 | −2.25 | – |
| Matrix metallopeptidase 9 | 3.48 | 1.95 |
| Mitogen-activated protein kinase kinase kinase 8 | 4.01 | 8.26 |
| Caspase 4, apoptosis-related cysteine peptidase | – | 8.62 |
| Heat shock protein 1A | – | −7.87 |
| Interferon regulatory factor 1 | – | 3.25 |
| Interferon regulatory factor 7 | – | 2.63 |
| Signal transduction | ||
| Interleukin-7 receptor | – | 9.81 |
| G protein–coupled receptor 35 | 2.77 | 6.49 |
| Rho family GTPase 1 | 3.24 | 8.83 |
| Interleukin-1 receptor, type II | 8.97 | 18.83 |
| G protein–coupled receptor 27 | 2.24 | 3.49 |
| Interleukin-10 receptor, α | 2.06 | 2.53 |
| Regulator of G protein signaling 1 | 4.64 | 8.55 |
| Suppressor of cytokine signaling 3 | 4.73 | 10.67 |
| Regulator of G protein signaling 2 | 2.36 | – |
| Janus kinase 2 | – | 2.41 |
| Interleukin-17 receptor | – | 2.61 |
| Mitogen-activated protein kinase kinase kinase kinase 2 | – | −15.93 |
| Phospholipase C, δ 3 | – | −2.55 |
| Chemokine (C-X-C motif) receptor 6 | – | 2.29 |
| Peroxisome proliferator activator receptor δ | – | 2.27 |
| Sphingosine kinase 1 | – | 6.67 |
| Suppressor of cytokine signaling 2 | – | 2.27 |
| Interleukin-4 receptor, α | – | 4.38 |
| Interleukin-8 receptor, β | – | 3.05 |
| Neuropilin 1 | – | −2.64 |
| Metallothionein 1 | 2.68 | 5.58 |
| Plasminogen activator, urokinase receptor | 2.47 | 4.42 |
| Phosphatidylinositol 3-kinase catalytic delta polypeptide | – | 3.39 |
| Mitogen-activated protein kinase kinase kinase kinase 5 | – | −2.69 |
| Mitogen-activated protein kinase kinase kinase 1 | – | 2.83 |
| Mitogen-activated protein kinase kinase kinase 6 | – | 9.08 |
| Mitogen-activated protein kinase 8 | – | −4.66 |
| Response to other organism | ||
| Neutrophilic granule protein | 4.70 | 27.44 |
| Response to fungus | ||
| Pentraxin-related gene | – | 11.74 |
| Cytokine- and chemokine-mediated signaling pathway | ||
| Colony-stimulating factor 2 receptor, β 1, low-affinity (granulocyte-macrophage) | 2.86 | 10.45 |
| Leukocyte immunoglobulin-like receptor, subfamily b (with TM and ITIM domains), member 3 | 2.57 | 6.62 |
| Colony-stimulating factor 2 receptor, β 2, low-affinity (granulocyte-macrophage) | – | 4.57 |
| Other | ||
| Lipocalin 2 | 2.66 | 11.97 |
| Arginase type II | 2.10 | 5.74 |
| Interleukin-1 family, member 9 | 5.18 | 19.02 |
| Matrix metallopeptidase 8 | 9.61 | 12.30 |
| Interferon-induced transmembrane protein 6 | 5.61 | 34.46 |
| s100 calcium binding protein A9 (calgranulin B) | 3.19 | 2.92 |
| Inhibitor of DNA binding 2 | – | 3.91 |
| Cytokine-inducible SH2-containing protein | – | 2.01 |
| Secretory leukocyte peptidase inhibitor | – | 3.76 |
| Amphiregulin | – | 3.59 |
| Interferon-induced transmembrane protein 2 | – | 2.51 |
| Mitogen-activated protein kinase kinase kinase 4 | – | −3.23 |
| Mitogen-activated protein kinase-activated protein kinase 3 | – | 2.36 |
| Mitogen-activated protein kinase kinase kinase 14 | – | 2.60 |
| Natriuretic peptide receptor 3 | – | 3.12 |
a
Values represent fold changes in gene expression in wild-type and PPTA−/− mice subjected to CLP-induced sepsis, compared with corresponding sham-operated mice. All the fold changes analyzed by GeneSpring 7.3 software were statistically significant (P < 0.05) compared with sham control.
b
Genes validated by RT-PCR.
c
Absence of a value (−) indicates that the fold change was less than two.
d
Negative values represent decreased mRNA levels compared with respective sham group values.